NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $23.80 -0.08 (-0.34%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$23.61▼$24.5550-Day Range$17.54▼$25.1052-Week Range$14.07▼$29.82Volume124,112 shsAverage Volume124,251 shsMarket Capitalization$86.85 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get LENZ Therapeutics alerts: Email Address LENZ Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside47.1% Upside$35.00 Price TargetShort InterestBearish9.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.81) to ($2.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 starsMedical Sector552nd out of 910 stocksBiological Products, Except Diagnostic Industry87th out of 155 stocks 3.6 Analyst's Opinion Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about LENZ Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.52% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 8.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LENZ. Previous Next 3.2 News and Social Media Coverage News SentimentLENZ Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for LENZ Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for LENZ on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.80) per share.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About LENZ Therapeutics Stock (NASDAQ:LENZ)LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More LENZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LENZ Stock News HeadlinesSeptember 2, 2024 | americanbankingnews.comShort Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Rises By 8.8%August 30, 2024 | seekingalpha.comLENZ Therapeutics: Upcoming PDUFA, Strong Data, Some RisksSeptember 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . August 27, 2024 | globenewswire.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesAugust 26, 2024 | investorplace.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024August 19, 2024 | insidermonkey.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for LENZ Therapeutics Amidst Strong Market Potential and Positive Product DataSeptember 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . August 15, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on LENZ Therapeutics (LENZ)August 15, 2024 | markets.businessinsider.comBuy Rating for LENZ Therapeutics on Promising Presbyopia Treatment and Market PotentialAugust 14, 2024 | globenewswire.comLENZ Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | globenewswire.comLENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of PresbyopiaAugust 7, 2024 | globenewswire.comLENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024June 10, 2024 | globenewswire.comLENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024May 30, 2024 | globenewswire.comLENZ Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 13, 2024 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call TranscriptMay 12, 2024 | msn.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call TranscriptSee More Headlines Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+47.1%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.95% Return on Assets-51.59% Debt Debt-to-Equity RatioN/A Current Ratio23.23 Quick Ratio23.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.02 per share Price / Book3.39Miscellaneous Outstanding Shares3,649,000Free Float2,248,000Market Cap$86.85 million OptionableN/A Beta0.39 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Evert B. Schimmelpennink (Age 52)President, CEO, Secretary & Director Comp: $886.54kMr. Shawn Olsson (Age 41)Chief Commercial Officer Comp: $532.13kMr. Marc G. Odrich M.D. (Age 65)Chief Medical Officer Comp: $576.95kMr. James W. McCollum (Age 69)Co-Founder & Director Mr. Gerald HornSenior Scientific Advisor & FounderMr. Daniel R. Chevallard CPA (Age 44)Chief Financial Officer Mr. Domenick PorfidiaVice President of SalesMr. David MurphySenior Director of Marketing & Alliance DevelopmentMr. Marvin J. Garrett (Age 73)Senior Vice President of Regulatory & Quality More ExecutivesKey CompetitorsAlvotechNASDAQ:ALVOSutro BiopharmaNASDAQ:STROVoyager TherapeuticsNASDAQ:VYGRKyverna TherapeuticsNASDAQ:KYTXSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsDeerfield Management Company L.P. Series CBought 17,353 shares on 8/15/2024Ownership: 0.476%Marshall Wace LLPBought 22,554 shares on 8/14/2024Ownership: 0.618%Squarepoint Ops LLCBought 10,477 shares on 8/14/2024Ownership: 0.287%Renaissance Technologies LLCBought 13,300 shares on 8/9/2024Ownership: 1.649%Dimensional Fund Advisors LPBought 13,653 shares on 8/9/2024Ownership: 1.019%View All Insider TransactionsView All Institutional Transactions LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.20 on January 1st, 2024. Since then, LENZ stock has increased by 46.9% and is now trading at $23.80. View the best growth stocks for 2024 here. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) released its earnings results on Wednesday, August, 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. Who are LENZ Therapeutics' major shareholders? Top institutional shareholders of LENZ Therapeutics include Wealth Enhancement Advisory Services LLC (2.28%), Renaissance Technologies LLC (1.65%), Bank of New York Mellon Corp (1.09%) and Dimensional Fund Advisors LP (1.02%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LENZ) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
